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Abstract (288 of 300 word limit) Introduction Cardiovascular disease (CVD) mortality is higher among breast cancer survivors (BCS) who receive chemotherapy compared to those not receiving chemotherapy. Anthracycline chemotherapy is of particular concern due to anthracycline-related impairment of vascular endothelial cells and dysregulation of the extracellular matrix. One strategy proven to offset these impairments is a form of exercise known as highintensity interval training (HIIT). HIIT improves endothelial function in non-cancer populations by decreasing oxidative stress, the main contributor to anthracycline-induced vascular dysfunction. The purpose of this pilot study is to assess the feasibility of an 8-week HIIT as well as HIIT-effects on endothelial function and extracellular matrix remodeling in BCS undergoing anthracycline chemotherapy.
Methods and Analysis
Thirty BCS are randomized to either HIIT, an 8-week HIIT intervention occurring 3 times per week (7 alternating bouts of 90% of peak power output followed by 10% peak power output), or delayed group (DEL). Feasibility of HIIT is assessed by: 1) the percentage of completed exercise sessions and 2) the number of minutes of exercise completed over the course of the study. Vascular function is assessed using brachial artery flow-mediated dilation (baFMD) and carotid intima media thickness (cIMT). Extracellular matrix remodeling is assessed by the level of matrix metalloproteinases (MMPs) in plasma. A repeated measures ANCOVA model will be performed with group (HIIT and DEL group) and time (pre/post assessment) as independent factors. We hypothesize that HIIT will be feasible in BCS undergoing AC, and that HIIT will improve endothelial function and extracellular matrix remodeling, compared to DEL group. Success of this study will provide evidence of feasibility and efficacy to support a larger definitive trial which will impact F o r p e e r r e v i e w o n l y cancer survivorship by decreasing anthracycline-induced vascular dysfunction, thereby benefiting cardiovascular markers that are related to CVD risk.
Ethics and dissemination This trial was approved by the University of Southern California Institutional
Review Board (HS-1500227).
Trial registration number NCT02454777

Strength
• This manuscript presents that high intensity interval training (HIIT) is a novel exercise strategy for breast cancer survivors undergoing anthracyclines lower volumes of HIIT compared to higher volumes of moderate continuous intensity exercise elicit better cardiovascular outcomes such as endothelial function and VO2max. Given the barrier of compliance in breast cancer survivors to regular exercise participation, HIIT is an intriguing alternative to traditional endurance-based exercise training for preventing cardiovascular side effects induced by anthracycline chemotherapy.
• Another strength of this manuscript is our focus on measuring vascular function using ultrasound imaging as well as molecular approaches in measuring matrix metalloproteinases. This measurements allow to identify whether HIIT can be used to improve extracellular matrix remodeling by targeting matrix metalloproteinases in breast cancer survivors undergoing treatment with anthracyclines.
Limitation
• Although this study will provide the first evidence of HIIT targeting vascular function in breast cancer survivors undergoing anthracycline chemotherapy, it is possible that we may demonstrate that endothelial function is maintained and not worsened during the HIIT intervention when compared to the DEL group.
• We recognize that poor adherence is a possibility given the time and effort needed to participate in an intervention study, in particular while undergoing anthracycline chemotherapy. 1,2 BCS undergoing chemotherapy are at even greater risk for CVD mortality. 3 BCS who receive chemotherapy have a 1.7-fold increased risk of CVD mortality than those who receive only radiotherapy and endocrine therapy. 1 In particular, anthracyclines, used in the treatment of early and advanced stage breast cancer, have negative cardiovascular consequences including increased risk for coronary heart disease and heart failure. 4, 5 Despite the potential cardiotoxicity, anthracyclines lead to higher survival and lower recurrence compared to non-anthracycline chemotherapy such as cyclophosphamide, methotrexate, and fluorouracil (CMF). 6 While the exact mechanisms by which anthracyclines cause cardiovascular dysfunction are still unknown, it is plausible that anthracyclines-induced oxidative stress may be responsible for endothelial dysfunction. 8 Anthracyclines' major mechanism of action is intercalation, in which the anthracycline inserts itself and binds to the DNA structure of a cell, inhibiting replication of cancer cells. 9 During anthracycline intercalation, oxidative stress is caused by the increased production of reactive oxygen species (ROS) which disrupts the regulation of nitric oxide, a major vasodilator. 10 The bioavailability of nitric oxide is reduced due to anthracycline-generated ROS that scavenge nitric oxide. This aspect of vascular endothelial dysfunction results in reduced brachial artery flow-mediated dilation (baFMD) and thickening of carotid intima media (cIMT), both of which can be assessed via ultrasound imaging. 11 Reduced baFMD and increased cIMT are evident in patients with CVD including hypertension, stroke, and heart failure. [12] [13] [14] Oxidative stress further increases damage in the extracellular matrix (ECM) which structurally supports surrounding endothelial cells. 15 ECM surrounding endothelial cells are mainly regulated by matrix metalloproteinases (MMPs). In particular, MMP-2 and MMP-9 are over-activated by ROS during anthracycline intercalation; this is another pathway contributing to endothelial dysfunction and thickening of the arterial wall by degrading connective tissue and basement membrane. [16] [17] [18] For example, anthracyclines markedly increased the activity of MMP-2 and MMP-9 in the carotid artery and peripheral blood following eight weeks of treatment in rats. Exercise is a safe and cost-effective strategy targeting many health outcomes (i.e., cardiorespiratory fitness and endothelial function) in BCS, 20 and therefore is a candidate to offset cancer treatment side effects given the burden of pharmaceutical treatments experienced by BCS. The benefits of exercise in BCS are wellestablished, and include improvements in physical function, quality of life, and activities of daily living. 21, 22 Exercise promotes vascular shear stress which decreases oxidative stress, 24 and thereby increases endothelial function measured by baFMD in CVD populations. 25, 26 High intensity interval training (HIIT) is an exercise strategy that maximizes exercise intensity by using bursts of concentrated effort alternated with active recovery periods. 27 HIIT allows patients to perform vigorous intensity exercise due to the 'on-off' pattern of exercise.
The "on" portion of HIIT typically involves 1-4 minutes performed at 80%-90% of peak power output (PPO) or maximum heart rate (MHR), followed by the "off" period of 1-3 minutes active break (10% PPO or 40-50-60%
of MHR). 28 HIIT is a clinically proven, safe and cost-effective intervention. 29, 30 This strategy has been shown to be more effective than moderate continuous intensity aerobic exercise for improving endothelial function among healthy adults and patients with CVD. 20, 31, 32 Overall, HIIT is a time-efficient exercise strategy that successfully increases endothelial function measured by baFMD in patients with severe CVD such as coronary heart disease, 19 heart failure, 31 and stroke, 30 without serious adverse events. Therefore, HIIT may have the capacity to improve endothelial function and atherosclerosis in BCS who are undergoing anthracycline chemotherapy.
Objectives This pilot study was designed to determine the feasibility of an 8-week HIIT intervention in BCS undergoing anthracycline chemotherapy. We hypothesize that an 8-week HIIT exercise intervention will be a feasible exercise training approach, whereby more than 50% of patients randomized to the HIIT intervention are able to complete an average of 70% (63/90 minutes) of total prescribed weekly minutes of exercise and >70%
(17/24 sessions) of total exercise sessions. Our second aim is to investigate the effect of an 8-week supervised HIIT intervention on endothelial function. We hypothesize that an 8-week HIIT exercise intervention will increase baFMD compared to the delayed (DEL) group. Lastly, we seek to investigate the effect of an 8-week
HIIT exercise intervention on ECM remodeling measured as levels of MMPs. We hypothesize that an 8-week
HIIT exercise intervention will improve circulating plasma MMP-2 and -9, compared to the DEL group. (ICORE) within 1-2 weeks prior to the start of the intervention period in a 1:1 ratio of allocation. Participants are randomly assigned using computer-generated investigator-blinded randomization to the HIIT group or DEL group. Participants randomized to the HIIT group visit the ICORE to complete 3 exercise sessions for a total of 90 minutes of weekly exercise during the 8-week intervention period. Participants randomized to the DEL group are asked to maintain their current level of physical activity, which should not exceed 30 minutes of total structured exercise per week. All participants return to the ICORE within one week following completion of the 8-week study period for post-testing. Outcome measures are obtained at baseline within 1 week prior to the first cycle of anthracyclines (week 0), at week 9, within 2-5 days from the last exercise session, and week 17 (8 weeks following post-study assessment.
Study Status Study enrollment, intervention and data collection are ongoing.
Participants Eligibility criteria
Participants who meet the following requirements are eligible: 1) women ≥ 18 years of age diagnosed (stage I-III) with a first primary invasive breast cancer; 2) receiving (neo)adjuvant anthracycline; 3) able to initiate exercise program within 1-2 weeks of initiation of chemotherapy, 4) less than 30 minutes of physical activity per week; 5) nonsmokers in previous 12 months; 6) willing to travel to the exercise facility at USC; 7) able to provide physician clearance to participate in the exercise program;. The exclusion criteria are: 1) history of chronic disease including diabetes, uncontrolled hypertension or thyroid disease; 2) weight reduction ≥ 10% within past 6 months; 3) metastatic disease; 4) overt CVD (myocardial infarction, stroke, angina); 5)
contraindications to exercise; 6) participation in regular exercise defined as greater than 30 minutes exercise per week screened by medical oncologist and PI.
Recruitment Strategy
We aim to recruit roughly 3 participants per month based on the estimated number of eligible patients that visit the breast clinics at USC; thus we anticipate reaching the targeted sample size within 10 months. Recruitment occurs primarily at the Los Angeles County Hospital and the USC NCCC Breast Cancer Clinic via onsite recruitment by the principal investigator (PI). Eligible patients scheduled for anthracycline are informed about the study at their medical oncology appointments to ensure successful screening and consent of eligible participants. Oncologists inform the PI when eligible participants who are interested in participating are identified. Interested participants are informed of the study details by the PI and patient eligibility are confirmed.
The conversation between the PI and the potential participants takes place in a private room at the hospital.
Written informed consent is obtained prior to study procedures.
Intervention
The HIIT protocol includes seven bouts of 1-minute high intensity exercise followed by 2 minutes of active recovery ( Figure 2) . A similar protocol was used by Boyne et al (2015) , who reported that HIIT significantly improved endothelial function in chronic stroke patients compared to moderate aerobic exercise. 30 All exercise sessions are supervised by the PI, a certified exercise trainer, are performed on a stationary bike, and takes place at USC ICORE. Based on peak PPO measured by a VO 2 max fitness test, exercise intensity is individually prescribed for HIIT intensity. Each session consists of a 5-minute warm-up performed at 10% PPO followed by a 21-minute HIIT stimulus (90% PPO/10% PPO), and 5-minute cool-down (10% PPO). 30 The HIIT bouts F o r p e e r r e v i e w o n l y consist of seven 1-minute high-intensity intervals performed at 90% PPO followed by a 2-minute low-intensity recovery interval performed at 10% PPO for the 21-minute HIIT duration.
Participants are encouraged to complete each exercise session with one full day of rest in between sessions, and are completed on days where participants have not received anthracyclines infusion. If a participant prefers to perform 2-3 consecutive sessions in a week due to anthracyclines-induced side effects (e.g., fatigue), this is documented on the exercise session form and the number of consecutive sessions in a week is counted. Power output, heart rate, rating of perceived exertion (RPE; Borg scale of [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , and total minutes of exercise completed are documented during each exercise session for each interval. Participants are encouraged to make up any missed sessions in the same week or during a 2-week make-up period (extending the intervention period to 10 weeks if needed), and have the ability to schedule their exercise sessions at days and times convenient for the participant alongside their individual treatment schedule. The DEL group is asked not to initiate a structured exercise program during the first 8-week study period and to maintain their current level of physical activity (< 30 minutes of total structured exercise per week). During this time the DEL group is asked to document their weekly physical activity on exercise logs. Following the first 8-weeks of intervention, the DEL is provided the same HIIT intervention.
Outcomes
All outcome assessments (Table 1) are performed by the PI.
Feasibility. Overall feasibility of HIIT is assessed using average weekly exercise completion (minutes/week) of all participants in HIIT group. Perceived limitations of enrollment in a previous study were lack of interest, too far to travel, and too busy. 32 Chemotherapy-induced fatigue can be another barrier to adherence. Thus, the HIIT program is considered feasible if more than 50% of patients randomized to the given condition are able to complete 70% (63/90 minutes) of prescribed weekly exercise (17/24 sessions). 33 If at least half of participants do not complete an average of 70% of the weekly exercise time, the exercise intervention is not classified as feasible. In the event that a participant is not able to complete the entire exercise session, the number of minutes (out of 30 minutes) completed during each exercise session is documented. 
Data Safety and Monitoring
All data are securely managed by the PI and are regularly monitored by the USC NCCC Data and Safety
Monitoring Committee. This ensures the safety of participants, validity of data, appropriate termination of study, evaluation of the current accrual relative to the planned total accrual, examination of all reported protocol violations and review of past audits. The safety of the exercise intervention is assessed and documented on the participant's exercise training chart by study personnel by recording of adverse events. Adverse events are identified at every exercise session and testing time point. Serious adverse events (events resulting in hospitalization) are reported within 24 hours to research governance committees (Institutional Review Boards and Data Monitoring and Safety Committee). 
Randomization
Once the patient has signed the informed consent and trial eligibility are confirmed, participants are randomly assigned by computer-generated investigator-blinded randomization assignments; randomization is stratified by neoadjuvant versus adjuvant anthracyclines treatment in a 1:1 allocation ratio by the Clinical Investigation Support Office (CISO) at USC NCCC. To prevent potential bias, study personnel do not have access to the randomization list.
Data management
Data are collected in a confidential format on paper charts and case report forms that are stored securely before and after being entered electronically into the secure web-based Research Electronic Data Capture application (REDCap, Vanderbilt University).
Statistical analysis
Feasibility of this study will be assessed using descriptive statistics (percentage of protocol-specified sessions and minutes completed). Paired t-tests will be used to evaluate the differences before and after intervention in each group. Repeated measures ANOVA on the trial outcomes will use a 2 (group: HIIT, DEL) x 2 (time: pre-, post-intervention) analysis. In a secondary analysis, participant baseline characteristics that are different across groups will be included as covariates in the statistical analyses with a repeated measures ANCOVA model. Residual analyses will be performed to test whether the assumptions of the model were met. If the residuals do not meet the assumptions (i.e. linearity, homoscedasticity, and normality), data transformations will be performed.
Discussion
This pilot trial was designed to determine the feasibility of HIIT in BCS undergoing anthracyclines, and secondarily assess exercise-induced changes in vascular function. HIIT is a novel exercise strategy for BCS undergoing anthracyclines which may allow clinical populations to perform vigorous intensity exercise due to the on-off' pattern of exercise. Importantly, lower volumes of HIIT compared to higher volumes of moderate continuous intensity exercise elicit better cardiovascular outcomes such as endothelial function and VO 2max ;
therefore HIIT is an effective and time-efficient exercise option. 44 Given the barrier of compliance in BCS to regular exercise participation, HIIT is an intriguing alternative to traditional endurance-based exercise training for increasing cardiovascular benefits requiring a shorter exercise duration.
45
Another innovative feature of this study is our focus on improving vascular function in BCS undergoing anthracyclines. HIIT in comparison to moderate continuous intensity exercise has successfully improved endothelial function in patients with CVD such as coronary heart disease, 19 heart failure, 46 and stroke. We hypothesize that the HIIT intervention is feasible in this population. The method of feasibility we set forth was based on previous studies that reported 68-80% adherence to exercise intervention in breast cancer We acknowledge potential limitations in our study design. Although this study will provide the first evidence of HIIT targeting vascular function in BCS undergoing AC, it is possible that we may demonstrate that endothelial function is maintained and not worsened during the HIIT intervention when compared to the DEL group. However, this as an important clinical finding given that HIIT may prevent worsening of CVD risk factors. Second, we recognize that poor adherence is a possibility given the time and effort needed to participate in an intervention study, in particular while undergoing chemotherapy. Therefore, we have accounted for a 15% attrition rate to allow for dropout participant; we do not expect a higher drop-out rate using data from previous studies that have conducted exercise training during chemotherapy. 51 Finally, recruitment of BCS can be challenging. [52] [53] [54] However, given our ongoing successful recruitment strategies including collaboration with the medical oncology team at USC, we believe a successful support team and recruitment plan are in place for the proposed study.
Ethics and dissemination
This study has been approved by USC Institutional Review Board (HS-15-00227), and follows the Health Insurance Portability and Accountability Act (HIPAA) mandate. This trial is registered at ClinicalTrials.gov (NCT02454777). All study participants are consented to participate in the study prior to data collection without any element of force, fraud and duress. Sufficient knowledge and comprehension of research procedures 
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Introduction Cardiovascular disease (CVD) mortality is higher among breast cancer survivors (BCS) who receive chemotherapy compared to those not receiving chemotherapy. Anthracycline chemotherapy is of particular concern due to anthracycline-related impairment of vascular endothelial cells and dysregulation of the extracellular matrix. One strategy proven to offset these impairments is a form of exercise known as highintensity interval training (HIIT). HIIT improves endothelial function in non-cancer populations by decreasing oxidative stress, the main contributor to anthracycline-induced vascular dysfunction. The purpose of this pilot study is to assess the feasibility of an 8-week HIIT as well as HIIT-effects on endothelial function and extracellular matrix remodeling in BCS undergoing anthracycline chemotherapy.
Methods and Analysis
Thirty BCS are randomized to either HIIT, an 8-week HIIT intervention occurring 3 times per week (7 alternating bouts of 90% of peak power output followed by 10% peak power output), or delayed group (DEL). Feasibility of HIIT is assessed by: 1) the percentage of completed exercise sessions and 2) the number of minutes of exercise completed over the course of the study. Vascular function is assessed using brachial artery flow-mediated dilation (baFMD) and carotid intima media thickness (cIMT). Extracellular matrix remodeling is assessed by the level of matrix metalloproteinases (MMPs) in plasma. A repeated measures ANCOVA model will be performed with group (HIIT and DEL group) and time (pre/post assessment) as independent factors. We hypothesize that HIIT will be feasible in BCS undergoing AC, and that HIIT will improve endothelial function and extracellular matrix remodeling, compared to DEL group. Success of this study will provide evidence of feasibility and efficacy to support a larger definitive trial which will impact cancer survivorship by decreasing anthracycline-induced vascular dysfunction, thereby benefiting cardiovascular markers that are related to CVD risk. 
Ethics and dissemination This trial was approved by the University of Southern California Institutional
Trial registration number NCT02454777
Strength
• This manuscript presents that high intensity interval training (HIIT) is a novel exercise strategy for breast cancer survivors undergoing anthracyclines since lower volumes of HIIT compared to higher volumes of moderate continuous intensity exercise elicit better cardiovascular outcomes such as endothelial function and VO 2 max.
• Given the barrier of compliance in breast cancer survivors to regular exercise participation, HIIT is an intriguing time-efficient alternative to traditional endurance-based exercise training for preventing cardiovascular side effects induced by anthracycline chemotherapy.
• Another strength of the proposed study is our focus on measuring vascular function using ultrasound imaging as well as molecular approaches in measuring matrix metalloproteinases. These measurements allow to identify whether HIIT can be used to improve extracellular matrix remodeling by targeting matrix metalloproteinases in breast cancer survivors undergoing treatment with anthracyclines.
Limitations
• We recognize that poor adherence is a possibility given the time and effort needed to participate in an intervention study, in particular while undergoing anthracycline chemotherapy. disease and heart failure. 4, 5 Despite the potential cardiotoxicity, anthracyclines lead to higher survival and lower recurrence compared to non-anthracycline chemotherapy such as cyclophosphamide, methotrexate, and fluorouracil (CMF). 6 While the exact mechanisms by which anthracyclines cause cardiovascular dysfunction are still unknown, it is plausible that anthracyclines-induced oxidative stress may be responsible for endothelial dysfunction. 7 Anthracyclines' major mechanism of action is intercalation, in which the anthracycline inserts itself and binds to the DNA structure of a cell, inhibiting replication of cancer cells. 8 During anthracycline intercalation, oxidative stress is caused by the increased production of reactive oxygen species (ROS) which disrupts the regulation of nitric oxide, a major vasodilator. 9 The bioavailability of nitric oxide is reduced due to anthracycline-generated ROS that scavenge nitric oxide. This aspect of vascular endothelial dysfunction results in reduced brachial artery flow-mediated dilation (baFMD) and thickening of carotid intima media (cIMT), both of which can be assessed via ultrasound imaging. 10 Reduced baFMD and increased cIMT are evident in patients with CVD including hypertension, stroke, and heart failure. [11] [12] [13] Oxidative stress further increases damage in the extracellular matrix (ECM) which structurally supports surrounding endothelial cells. 14 ECM surrounding endothelial cells are mainly regulated by matrix metalloproteinases (MMPs). In particular, MMP-2 and MMP-9 are over-activated by ROS during anthracycline intercalation; this is another pathway contributing to endothelial dysfunction and thickening of the arterial wall by degrading connective tissue and basement membrane. [15] [16] [17] For example, anthracyclines markedly increased the activity of MMP-2 and MMP-9 in the carotid artery and peripheral blood following eight weeks of treatment in rats. 28 HIIT allows patients to perform vigorous intensity exercise due to the 'on-off' pattern of exercise. The "on" portion of HIIT typically involves 1-4 minutes performed at 80%-90% of peak power output (PPO) or maximum heart rate (MHR), followed by the "off" period of 1-3 minutes active break (10% PPO or 40-50-60% of MHR). 29 HIIT is a clinically proven, safe and cost-effective intervention in patients with stroke or heart failure. [29] [30] [31] [32] This strategy has been shown to be more effective than moderate continuous intensity aerobic exercise for improving endothelial function among healthy adults and patients with CVD. 19, 30, 33 Overall, HIIT is a time-efficient exercise strategy that successfully increases endothelial function measured by baFMD in patients with severe CVD such as coronary heart disease, 19 heart failure, 34 and stroke, 30 without serious adverse events. Therefore, HIIT may have the capacity to improve endothelial function and atherosclerosis in BCS who are undergoing anthracycline chemotherapy. While the benefits of HIIT have been investigated on cancerrelated fatigue 29, 35 and health-related quality of life 36 in cancer patients, there is no specific evidence demonstrating the feasibility HIIT in BCS undergoing anthracycline chemotherapy. Further, novel aspects of our exercise program design warrant an assessment of feasibility. Specifically, the prescribed HIIT intensity in our pilot study is based on peak power output which differs from previous studies which quantified intensity using predicted max heart rate, 37 or ratings of perceived exertion.
Introduction
35
Objectives This pilot study was designed to determine the feasibility of an 8-week HIIT intervention in BCS undergoing anthracycline chemotherapy. We hypothesize that an 8-week HIIT exercise intervention will be a feasible exercise training approach, whereby more than 50% of patients randomized to the HIIT intervention are able to complete an average of 70% (63/90 minutes) of total prescribed weekly minutes of exercise and >70% (17/24 sessions) of total exercise sessions. Our second aim is to investigate the effect of an 8-week supervised HIIT intervention on endothelial function. We hypothesize that an 8-week HIIT exercise intervention will increase baFMD compared to the delayed (DEL) group. Lastly, we seek to investigate the effect of an 8-week HIIT exercise intervention on ECM remodeling measured as levels of MMPs. We hypothesize that an 8-week
HIIT exercise intervention will improve circulating plasma MMP-2 and -9, compared to the DEL group.
Methods and Analysis
Experimental Design (Figure 1 ) Participants are recruited from the breast cancer clinics at the Norris Comprehensive Cancer Center (NCCC) and the Los Angeles County medical center. Our recruitment strategy is to closely collaborate with our medical oncology team. Specifically, when the patients come for their medical oncology appointment, they are informed about the study by the medical staff including medical oncologists, fellow, nurse or PI, with the PI on hand at all clinic times to ensure successful screening and consent of eligible participants. Following informed consent and determination of eligibility at the screening visit, eligible and consenting participants complete their baseline test at the Integrative Center for Oncology Research in Exercise (ICORE) within 1-2 weeks prior to the start of the intervention period in a 1:1 ratio of allocation. Participants are randomly assigned using computer-generated investigator-blinded randomization to the HIIT group or DEL group. Participants randomized to the HIIT group visit the ICORE to complete 3 exercise sessions for a total of 90 minutes of weekly exercise during the 8-week intervention period. Participants randomized to the DEL group are asked to maintain their current level of physical activity, which should not exceed 30 minutes of total structured exercise per week. All participants return to the ICORE within one week following completion of the 8-week study period for post-testing. Outcome measures are obtained at baseline within 1 week prior to the first cycle of anthracyclines (week 0), at week 9, within 2-5 days from the last exercise session, and week 17 (8 weeks following post-study assessment.
22,38
Study Status Study enrollment, intervention and data collection are ongoing. Patient or public were not involved in the development of the research question, study design, and recruitment process.
Patient and Public Involvement
Participants Eligibility criteria
Participants who meet the following requirements are eligible: 1) women ≥ 18 years of age diagnosed (stage I-III) with a first primary invasive breast cancer; 2) receiving (neo)adjuvant anthracycline; 3) able to initiate exercise program within 1-2 weeks of initiation of chemotherapy, 4) less than 30 minutes of physical activity per week; 5) nonsmokers in previous 12 months; 6) willing to travel to the exercise facility at USC; 7) able to provide physician clearance to participate in the exercise program;. The exclusion criteria are: 1) history of chronic disease including diabetes, uncontrolled hypertension or thyroid disease; 2) weight reduction ≥ 10%
within past 6 months; 3) metastatic disease; 4) overt CVD (myocardial infarction, stroke, angina); 5)
contraindications to exercise; 6) participation in regular exercise defined as greater than 30 minutes exercise per week screened by medical oncologist and PI and/or participation in other lifestyle interventions such as psychosocial or diet interventions.
Recruitment Strategy
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Intervention
The HIIT protocol includes seven bouts of 1-minute high intensity exercise followed by 2 minutes of active recovery (Figure 2) . A similar protocol was used by Boyne et al (2015) , who reported that HIIT significantly improved endothelial function in chronic stroke patients compared to moderate aerobic exercise. 30 All exercise sessions are supervised by the PI, a certified exercise trainer, are performed on a stationary bike, and takes place at USC ICORE. Based on peak PPO measured by a VO 2 max fitness test, exercise intensity is individually prescribed for HIIT intensity. Each session consists of a 5-minute warm-up performed at 10% PPO followed by a 21-minute HIIT stimulus (90% PPO/10% PPO), and 5-minute cool-down (10% PPO). 30 The HIIT bouts consist of seven 1-minute high-intensity intervals performed at 90% PPO followed by a 2-minute low-intensity recovery interval performed at 10% PPO for the 21-minute HIIT duration.
Participants are encouraged to complete each exercise session with one full day of rest in between sessions, and are completed on days where participants have not received anthracyclines infusion. If a participant prefers to perform 2 or 3 consecutive sessions in a given week (vs 1 session every other day) due to anthracyclines-induced side effects (e.g., fatigue), this is documented on the exercise session form and the number of consecutive sessions in a week is counted. Power output, heart rate, rating of perceived exertion (Borg scale of [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , and total minutes of exercise completed are documented during each exercise session for each interval. Participants are encouraged to make up any missed sessions in the same week or during a 2-week make-up period (extending the intervention period to 10 weeks if needed), and have the ability to schedule their exercise sessions at days and times convenient for the participant alongside their individual treatment schedule.
The DEL group is asked not to initiate a structured exercise program during the first 8-week study period and to maintain their current level of physical activity (< 30 minutes of total structured exercise per week). During this time the DEL group is asked to document their weekly physical activity on exercise logs. Following the first 8-weeks of intervention, the DEL is provided the same HIIT intervention.
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Feasibility. Overall feasibility of HIIT is assessed using average weekly exercise completion (minutes/week) of all participants in HIIT group. Perceived limitations of enrollment in a previous study were lack of interest, too far to travel, and too busy. 39 Chemotherapy-induced fatigue can be another barrier to adherence. Thus, the HIIT program is considered feasible if more than 50% of patients randomized to the given condition are able to complete 70% (63/90 minutes) of prescribed weekly exercise (17/24 sessions). 40 This method of feasibility was set forth based on previous studies in breast cancer survivors that reported the adherence of exercise intervention ranges from 68% to 80%. Particularly, exercise adherence is lower in the studies which included cancer survivors undergoing chemotherapy, whereas higher adherence was reported in cancer survivors who completed cancer treatment. 39 If at least half of participants do not complete an average of 70% of the weekly exercise time, the exercise intervention is not classified as feasible. In the event that a participant is not able to complete the entire exercise session, the number of minutes (out of 30 minutes) completed during each exercise session is documented.
Arterial wall thickening: cIMT. After a 12-hr fast and abstinence from alcohol, caffeine, and vitamins, arterial wall thickening is evaluated measuring cIMT. Participants lie in the supine position on the plinth to noninvasively image common carotid arteries (left and right) using B-mode ultrasound (GE LOGIQ e). The ultrasound scan is used to measure lumen diameter, intima media thickness, and presence and extent of carotid plaques. Large interventional studies have shown that cross-sectional cIMT is positively associated with CVD risk including stroke. 41, 42 To measure cIMT, the carotid bifurcation is detected as a reference; a region of interest (ROI) is identified by the far (posterior) arterial wall along a 10mm section proximal to the carotid bifurcation (the average value of 3 measurements). Using auto detection software developed by GE Healthcare, an ultrasound caliper automatically detects the ROI (where a bright-dark bright pattern corresponds to the intima media adventitia layers of the arterial walls). 43 This auto detection technique provides an accurate measure of the cIMT and reduces the subjectivity of manual approaches by detecting the cIMT throughout the artery length, rather than using only a few points of cIMT (intraclass correlation coefficient of repeated measurements over a week: 0.95). Corporation, Austin, Texas). Although we do not target the activity of TIMPs, the concentration of TIMPs is used to conduct a sensitivity analysis of the ratio of MMPs/TIMPs, which represents a single value of MMPs at the global proteolytic balance. 47 All samples are assayed in duplicate wells (25 uL per well), and the mean of these results is used. MMP concentrations are calculated by reference to an eight-point spline fit curve. We store additional blood samples for future analysis of biomarkers related to insulin sensitivity.
Additional Outcomes
Cardiorespiratory fitness. All participants complete a baseline cardiorespiratory fitness test (Week 0) using a maximal effort cycling protocol to measure maximal oxygen uptake (VO 2 max), used in order to prescribe the relative exercise intensity. 48, 49 The specific protocol comprises a 10W increase in workload every one minute, starting at 40W. This testing is performed with standard equipment for indirect calorimetry (Parvo Medics Inc, Salt Lake City, UT) in an incremental protocol until exhaustion (respiratory exchange ratio>1.10, heart rate ±10/min predicted MHR, ratings of perceived exertion 17; in 6-20 ratings) on recumbent bike. Before the fitness test is performed, participants are familiarized with the testing protocol using standardized verbal instructions indicating the duration of each stage, maintaining the same RPM throughout the test, and increases of torque during the test. Participants are instructed in proper pedaling, high and low intensity periods, with a resistance corresponding to 10-20% of PPO and a pedal rate of 60rpm. 50 Following this testing, PPO is obtained at the last stage of maximal cycling testing, and the PPO is used to prescribe intensity of HIIT.
Body composition. Body compositions (lean body mass and fat mass) are measured using an InBody 770 bioelectrical impedance scale (Biospace, Cerritos, CA). These measures will be used as possible covariates and to determine if the improvement in vascular function is independent of body composition. Participants are scanned using standard imaging and positioning protocols recommended by the manufacturer. BMI in kg/m 2 is calculated from height and weight measurements using a medical scale (Detecto® 437, Webb City, MO). 
Sample Size
Data from this pilot trial will provide estimates of group means, SDs, and group differences for use in designing a larger definitive efficacy. With a sample size of 30 subjects (15 per group) in this pilot study, we are able to estimate means for our outcome variables (within either group of 15) with a 95% confidence interval of ±0.51 standard deviation (SD) units. At a 2-sided alpha level of 0.05, we are able to estimate treatment group difference in the outcome means with a 95% confidence interval of ±0.72 SD units. Since this study is conducted as a pilot study, it is designed to inform feasibility and provide estimates of intervention effects.
Randomization
Once the patient has signed the informed consent and trial eligibility are confirmed, participants are randomly assigned by computer-generated investigator-blinded randomization assignments; randomization is stratified by 
Data management
Statistical analysis
Feasibility of this study will be assessed using descriptive statistics (percentage of protocol-specified sessions and minutes completed). Paired t-tests will be used to evaluate the differences before and after intervention in each group. Repeated measures ANOVA on the trial outcomes will use a 2 (group: HIIT, DEL) x 2 (time: pre-, post, follow up intervention) analysis. In a secondary analysis, participant baseline characteristics that are different across groups will be included as covariates in the statistical analyses with a repeated measures ANCOVA model. Residual analyses will be performed to test whether the assumptions of the model were met.
If the residuals do not meet the assumptions (i.e. linearity, homoscedasticity, and normality), data transformations will be performed.
Discussion
Within clinical settings, HIIT is traditionally prescribed using predicted max heart rate or ratings of perceived exertion in previous clinical settings. 33, 37, [51] [52] [53] However, given that individuals have different resting/maximal heart rates and heart rate recovery, especially during chemotherapy treatment, utilizing heart rate as an indicator of intensity in this population does not guarantee a similar absolute or relative intensity to individuals not undergoing chemotherapy. PPO has become a more precise measure to prescribe and monitor exercise intensity We hypothesize that the HIIT intervention is feasible in this population. The method of feasibility we set forth was based on previous studies that reported 68-80% adherence to exercise intervention in breast cancer patients. 39, 59, 60 Exercise adherence was notably lower in studies which included cancer patients undergoing chemotherapy (68-72%), 39,59 whereas higher adherence was reported in patients who had completed cancer treatment (83-95%). 38, 60 Because exercise adherence may be disrupted by cancer treatment and its adverse We acknowledge potential limitations in our study design. Although this study will provide the first evidence of HIIT targeting vascular function in BCS undergoing AC, it is possible that we may demonstrate that endothelial function is maintained and not worsened during the HIIT intervention when compared to the DEL group. However, this as an important clinical finding given that HIIT may prevent worsening of CVD risk factors. Second, we recognize that poor adherence is a possibility given the time and effort needed to participate in an intervention study, in particular while undergoing chemotherapy. Therefore, we have accounted for a 15% attrition rate to allow for dropout participant; we do not expect a higher drop-out rate using data from previous studies that have conducted exercise training during chemotherapy. 61 Finally, recruitment of BCS can be challenging. [62] [63] [64] However, given our ongoing successful recruitment strategies including collaboration with the medical oncology team at USC, we believe a successful support team and recruitment plan are in place for the proposed study.
Ethics and dissemination
This study has been approved by USC Institutional Review Board (HS-15-00227), and follows the Health Insurance Portability and Accountability Act (HIPAA) mandate. This trial is registered at ClinicalTrials.gov (NCT02454777). All study participants are consented to participate in the study prior to data collection without any element of force, fraud and duress. Sufficient knowledge and comprehension of research procedures including purpose, methods, and means by which it is to be conducted are provided. Any potential risk, benefits, discomfort and hazards are reasonably be explained by the principal investigator. Participants are not excluded from the study based, race, religion, or socioeconomic status. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
